Global Healthcare Analyst

Tina Banerjee

Equity research analyst having 15+ years of experience, with an interest on fundamentally strong global healthcare companies. I have been helping investors to find future winners in healthcare space to grow their wealth by focusing on the strength and potential of the business models of the companies. My initiating coverage reports and pitch help investors to know ‘what to buy’, ‘why to buy’, and ‘when to buy’. My clients always remain on top of the sector with the help of my timely and detailed notes on earnings or any news update. I also provide broader view on the entire healthcare sector through periodic thematic reports.

Mani Inc (7730 JP): Margins Expand in Q1FY26, Dia-Bur Sale Resume in China, FY26 Guidance Reiterated

Mani Inc (7730 JP): China Dia-Bur Sale Resumption Positively Impact H1FY26, FY26 Guidance Reiterated

Mani Inc (7730 JP): FY26 Guidance Point Towards a Recovery, Unleashing A Long-Term Play Mode

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/mani-inc" target="_blank" data-smartkarma-citation="entities:6534:1" rel="noopener">Mani Inc (7730 JP)</a> 9MFY26 revenue increased 9.5% YoY to ¥24.4B while operating margin improved 320bps to 30.7%. Dental segments reported margin improvement from 10.4% to 18.2%.</li>
<li>Underperformance of dental segment because of recall and margin erosion had been a major concern. Q3FY26 sales recovered to around 87% of the pre-recall level.</li>
<li>FY26 guidance witnessed upward revision. They now expect FY26 revenue to be ¥32.9B (up 9.8% YoY), operating profit at ¥9.7B (up 18%) and net income to be ¥6.8B (up 46%).</li>
</ul>



Mani Inc (7730 JP) 9MFY26 revenue increased 9.5% YoY to ¥24.4B while operating margin improved 320bps to 30.7%. Dental segments reported margin improvement from 10.4% to 18.2%.
Underperformance of dental segment because of recall and margin erosion had been a major concern. Q3FY26 sales recovered to around 87% of the pre-recall level.
FY26 guidance witnessed upward revision. They now expect FY26 revenue to be ¥32.9B (up 9.8% YoY), operating profit at ¥9.7B (up 18%) and net income to be ¥6.8B (up 46%).


Mani Inc (7730 JP): 9MFY26 Results Underline Recovery, FY26 Guidance Revised Upward